Wei Xiong, MD
Neurology · Cleveland, OHNPI 1487706610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by UCB, Inc. at 26.0% of the total. 2025 is the largest year on record at $1,024, 2.7 times the $383 reported in 2019.
Across 182 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$914
- AstraZeneca$702
- Lilly USA, LLC$237
- Genentech USA, Inc.$228
- Pfizer$179
- Amgen$174
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,518100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 42 | $914 |
| AstraZeneca(2 entities) | 40 | $702 |
| Lilly USA, LLC | 12 | $237 |
| Genentech USA, Inc. | 10 | $228 |
| Pfizer | 12 | $179 |
| Amgen | 8 | $174 |
| Averitas Pharma Inc. | 7 | $167 |
| Jazz Pharmaceuticals Inc. | 8 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| Argenx US, Inc. | 4 | $84 |
| SK Life Science, Inc. | 4 | $82 |
| CSL Behring | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $75 |
| Portola Pharmaceuticals, LLC | 4 | $53 |
| Sanofi | 3 | $49 |
| Neurelis, Inc. | 3 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Lundbeck LLC | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
How this compares
$3,518 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.